Dimitrios  Tzalis

Dr. Dimitrios Tzalis


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Drug Discovery Today
Verified
Journal Article
Open access
AKAnna Karawajczyk
Anna Karawajczyk
FGFabrizio Giordanetto
Fabrizio Giordanetto
JBJorg Benningshof
Jorg Benningshof
DHDaniel Hamza
Daniel Hamza
TKTuomo Kalliokoski
Tuomo Kalliokoski
DDimitrios Tzalis
Dimitrios Tzalis
High-throughput screening (HTS) represents a major cornerstone of drug discovery. The availability of an innovative, relevant and high-quality compound collection to be screened often dictates the final fate of a drug discovery campaign. Given that the chemical space to be sampled in research programs is practically infinite and sparsely populated, significant efforts and resources need to be invested in the generation and maintenance of a competitive compound collection. The European Lead Factory (ELF) project is addressing this challenge by leveraging the diverse experience and know-how of academic groups and small and medium enterprises (SMEs) engaged in synthetic and/or medicinal chemistry. Here, we describe the novelty, diversity, structural complexity, physicochemical characteristics and overall attractiveness of this first batch of ELF compounds for HTS purposes.

20 August 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MWMadita Wolter
Madita Wolter
DVDario Valenti
Dario Valenti
PCPeter J. Cossar
Peter J. Cossar
LLLaura M. Levy
Laura M. Levy
SHStanimira Hristeva
Stanimira Hristeva
COChristian Ottmann
Christian Ottmann
Small‐molecule stabilization of protein–protein interactions (PPIs) is a promising concept in drug discovery, however the question how to identify or design chemical starting points in a “bottom‐up” approach is largely unanswered. We report a novel concept for identifying initial chemical matter for PPI stabilization based on imine‐forming fragments. The imine bond offers a covalent anchor for site‐directed fragment targeting, whereas its transient nature enables efficient analysis of structure–activity relationships. This bond enables fragment identification and optimisation using protein crystallography. We report novel fragments that bind specifically to a lysine at the PPI interface of the p65‐subunit‐derived peptide of NF‐κB with the adapter protein 14‐3‐3. Those fragments that subsequently establish contacts with the p65‐derived peptide, rather than with 14‐3‐3, efficiently stabilize the 14‐3‐3/p65 complex and offer novel starting points for molecular glues.

2 June 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MWMadita Wolter
Madita Wolter
DVDario Valenti
Dario Valenti
PCPeter J. Cossar
Peter J. Cossar
SHStanimira Hristeva
Stanimira Hristeva
LLLaura M. Levy
Laura M. Levy
COChristian Ottmann
Christian Ottmann
Protein–protein modulation has emerged as a proven approach to drug discovery. While significant progress has been gained in developing protein–protein interaction (PPI) inhibitors, the orthogonal approach of PPI stabilization lacks established methodologies for drug design. Here, we report the systematic ″bottom-up″ development of a reversible covalent PPI stabilizer. An imine bond was employed to anchor the stabilizer at the interface of the 14-3-3/p65 complex, leading to a molecular glue that elicited an 81-fold increase in complex stabilization. Utilizing protein crystallography and biophysical assays, we deconvoluted how chemical properties of a stabilizer translate to structural changes in the ternary 14-3-3/p65/molecular glue complex. Furthermore, we explore how this leads to high cooperativity and increased stability of the complex.

1 April 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DVDario Valenti
Dario Valenti
SHStanimira Hristeva
Stanimira Hristeva
DDimitrios Tzalis
Dimitrios Tzalis
COChristian Ottmann
Christian Ottmann

6 October 2018 in Molecules
Verified
Journal Article
Open access
PDF file
SSSilvia Stotani
Silvia Stotani
VGViviana Gatta
Viviana Gatta
FMFederico Medda
Federico Medda
MPMohan Padmanaban
Mohan Padmanaban
AKAnna Karawajczyk
Anna Karawajczyk
Simona CollinaSimona Collina
Simona Collina
Resistance to antibiotics is an increasingly serious threat to global public health and its management translates to significant health care costs. The validation of new Gram-negative antibacterial targets as sources for potential new antibiotics remains a challenge for all the scientists working in this field. The interference with bacterial Quorum Sensing (QS) mechanisms represents a potentially interesting approach to control bacterial growth and pursue the next generation of antimicrobials. In this context, our research is focused on the discovery of novel compounds structurally related to (S)-4,5-dihydroxy-2,3-pentanedione, commonly known as (S)-DPD, a small signaling molecule able to modulate bacterial QS in both Gram-negative and Gram-positive bacteria. In this study, a practical and versatile synthesis of racemic DPD is presented. Compared to previously reported syntheses, the proposed strategy is short and robust: it requires only one purification step and avoids the use of expensive or hazardous starting materials as well as the use of specific equipment. It is therefore well suited to the synthesis of derivatives for pharmaceutical research, as demonstrated by four series of novel DPD-related compounds described herein.

19 January 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
AKAnna Karawajczyk
Anna Karawajczyk
KOKristina M. Orrling
Kristina M. Orrling
JVJon S. B. de Vlieger
Jon S. B. de Vlieger
TRTon Rijnders
Ton Rijnders
DDimitrios Tzalis
Dimitrios Tzalis
The European Lead Factory (ELF) is a public–private partnership (PPP) that provides researchers in Europe with a unique platform for translation of innovative biology and chemistry into high quality starting points for drug discovery. It combines an exceptional collection of small molecules, high throughput screening infrastructure and hit follow-up capabilities to advance research projects from both private companies and publicly funded researchers. By active interactions with the wider European life science community, ELF connects and unites bright ideas, talent, and experience from several disciplines. As a result, ELF is a unique, collaborative lead generation engine that has so far resulted in >4500 hit compounds with a defined biological activity from 83 successfully completed high throughput screening and hit evaluation campaigns. The PPP has also produced more than 120,000 novel innovative library compounds that complement the 327,000 compounds contributed by the participating pharmaceutical companies. Intrinsic to its setup, ELF enables breakthroughs in areas with unmet medical and societal needs, where no individual entity would be able to create a comparable impact in such a short time.